Puerarin Protects Against LPS-Induced Vascular Endothelial Cell Hyperpermeability via Preventing Downregulation of Endothelial Cadherin
In the present study, we aimed to investigate the effects of puerarin on the hyperpermeability of vascular endothelial cells induced by lipopolysaccharide (LPS) and its underlying mechanisms. Human umbilical vein endothelial cells (HUVECs) were pre-incubated with puerarin (25, 50, and 100 μM) for 1 h, and then exposed to LPS (1 μg/mL). The monolayer permeability of endothelial cells was assessed by measuring the paracellular flux of FITC-dextran 40,000 (FD40). The expression of vascular endothelial cadherin (VE-cadherin) in HUVECs was examined by Western blotting analysis. A total of 18 mice were randomly assigned into three groups as follows: control group, LPS group, and puerarin group. The pulmonary W/D ratio (wet-to-dry weight ratios) was calculated, and the lung morphology was examined. The levels of TNF-α and IL-1β in cell supernatant and mouse serum were determined by ELISA. Compared with the control group, LPS obviously increased the flux of FD40 and the monolayer permeability, raised the levels of TNF-α and IL-1β in cell supernatant, and reduced the VE-cadherin expression in HUVECs. However, puerarin (25, 50, and 100 μM) was able to relieve such LPS-induced increase in flux of FD40 and then reduce the hyperpermeability. Puerarin decreased the levels of TNF-α and IL-1β in cell supernatant and increased the VE-cadherin expression in HUVECs (P < 0.05). Moreover, LPS obviously increased the levels of TNF-α and IL-1β in mouse serum and elevated the pulmonary W/D ratios, resulting in lung injury. However, all of above-mentioned LPS-induced changes were improved by puerarin pre-treatment. Puerarin could alleviate LPS-induced hyperpermeability in endothelial cells via preventing downregulation of endothelial cadherin.
KEY WORDSpuerarin lipopolysaccharide permeability inflammatory factor VE-cadherin
The study was supported by Health Commission Foundation of Hunan Province (grant no. B2017043), Hunan College Students Research Learning and Innovative Experiment Program (grant no. 205-722), and the Scientific Research Fund of Hunan Provincial Education Department (grant no. 18C1014).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Fleischmann, C., A. Scherag, N.K. Adhikari, C.S. Hartog, T. Tsaganos, P. Schlattmann, D.C. Angus, and K. Reinhart. 2016. International Forum of Acute Care Trialists: assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. American Journal of Respiratory and Critical Care Medicine 193: 259–272.CrossRefGoogle Scholar
- 2.Margraf, A., J.M. Herter, K. Kuhne, A. Stadtmann, T. Ermert, M. Wenk, M. Meersch, H. Van Aken, A. Zarbock, and J. Rossaint. 2018. 6% hydroxyethyl starch (hes 130/0.4) diminishes glycocalyx degradation and decreases vascular permeability during systemic and pulmonary inflammation in mice. Critical Care 22 (1): 111.CrossRefGoogle Scholar
- 5.Reglero-Real, N., B. Colom, J.V. Bodkin, and S. Nourshargh. 2016. Endothelial Cell Junctional Adhesion Molecules: Role and Regulation of Expression in Inflammation. Arterioscler Thromb Vasc Biol 36 (10): 2048–2057.Google Scholar
- 6.Vila Cuenca, M., J. van Bezu, Beelen RHJ, M.G. Vervloet, and P.L. Hordijk. 2019. Stabilization of cell-cell junctions by active vitamin d ameliorates uraemia-induced loss of human endothelial barrier function. Nephrol Dial Transplant 34(2):252-264Google Scholar
- 7.Matsuda, S., T. Fujita, M. Kajiya, K. Kashiwai, K. Takeda, H. Shiba, and H. Kurihara. 2015. Brain-derived neurotrophic factor prevents the endothelial barrier dysfunction induced by interleukin-1beta and tumor necrosis factor-alpha. Journal of Periodontal Research 50 (4): 444–451.CrossRefGoogle Scholar
- 8.Choy, K.W., Y.S. Lau, D. Murugan, P.M. Vanhoutte, and M.R. Mustafa. 2018. Paeonol attenuates LPS-induced endothelial dysfunction and apoptosis by inhibiting BMP4 and TLR4 signaling simultaneously but independently. The Journal of Pharmacology and Experimental Therapeutics 364 (3): 420–432.CrossRefGoogle Scholar
- 9.Zhang, W., Y. Zhang, X. Guo, Z. Zeng, J. Wu, Y. Liu, J. He, R. Wang, Q. Huang, and Z. Chen. 2017. Sirt1 protects endothelial cells against LPS-induced barrier dysfunction. Oxidative Medicine and Cellular Longevity 2017: 4082102.Google Scholar
- 11.Fu, C., S. Hao, X. Xu, J. Zhou, Z. Liu, H. Lu, L. Wang, W. Jin, and S. Li. 2018. Activation of sirt1 ameliorates lps-induced lung injury in mice via decreasing endothelial tight junction permeability. Acta Pharmacologica Sinica. https://doi.org/10.1038/s41401-018-0045-3.
- 15.Deng, H.F., and W.L. Zhang. 2011. Protective effect and mechanism of puerarin against lysophosphatidylcholine induced vascular endothelial cell damage. Pharmacol and Clinics of Chin Materia Medica 27 (2): 40–43.Google Scholar
- 16.Deng HF, Ou YC, Zhou Q, Li J, Li XF, He HJ, Xie M, Lu XH. Protection of puerarin on impaired vascular endothelial function induced by glycosylated protein. Chinese Pharmaceutical Journal, 2014;49 (7):559–563.Google Scholar
- 17.LU, S.L. 2015. Effect of puerarin on platelet granule membrane protein, lysosome membrane protein, plasma plasminogen activator inhibitor and C-reactive protein of patients with unstable angina pectoris. Chin J Chin Med 30 (12): 1818–1820.Google Scholar